Clinical trials: Residual Disease
B-Cell Acute Lymphoblastic Leukemia
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD…
- Trial name
- CASSIOPEIA (NCT03876769)
- Testing
- CTL019
- Where
- 43 sites in United States, Belgium and 9 more
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Kidney Disease
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease
- Trial name
- NCT01752985
- Testing
- BMS-813160
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 319 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
A Study of Patients With Major Depressive Disorder and Residual Apathy
The purpose of this study is to provide a comparison of the apathy, depression, and functional outcomes associated with switching to duloxetine or escitalopram in patients who have previously responded to treatment with a…
- Trial name
- NCT00985504
- Testing
- Duloxetine, Escitalopram
- Where
- 15 sites in Australia, Canada and 3 more
- Volunteers
- 483 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like…
- Trial name
- NCT04634435
- Testing
- BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
This study aims to Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants with Residual Invasive Disease Following Neoadjuvant Therapy，This study will examine…
- Trial name
- NCT06126640
- Testing
- SHR-A1811, Trastuzumab Emtansine
- Where
- 2 sites in China
- Volunteers
- 1,615 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Schizophrenia
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple…
- Trial name
- NCT01244828
- Testing
- Asenapine
- Volunteers
- 157 people
- Sponsor
- Organon and Co
CML, Chronic Phase
Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.
- Trial name
- ICT10 (NCT02949570)
- Testing
- Inecalcitol
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Hybrigenics Corporation
Aphakia, Presbyopia
Evaluation of AcrySof IQ Vivity Extended Vision Intraocular Lenses
The purpose of this post-market study is to describe the long-term safety and performance of AcrySof IQ Vivity and AcrySof IQ Vivity Toric intraocular lens (IOL) models in a real-world setting through routine clinical practice.
- Conditions
- Aphakia, Presbyopia, Residual Refractive Cylinder
- Trial name
- NCT06541795
- Testing
- AcrySof IQ Vivity Extended Vision IOL
- Where
- United States
- Sponsor
- Alcon Research
Acute Myeloid Leukemia
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
The primary purpose of this study was to test the hypothesis that preemptive treatment with sabatolimab, alone or in combination with azacitidine, when administered to participants with Acute myeloid leukemia (AML)/secondary AML…
- Trial name
- NCT04623216
- Testing
- Sabatolimab, Azacitidine
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
- Trial name
- BLAST (NCT01207388)
- Testing
- Blinatumomab
- Where
- 75 sites in Austria, Belgium and 9 more
- Volunteers
- 116 people
- Sponsor
- Amgen Research (Munich) GmbH
Leukemia, Myeloid
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
CC-90011-AML-002 is a Phase 1/2, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently with Venetoclax and Azacitidine.
- Trial name
- NCT04748848
- Testing
- CC-90011, Venetoclax, Azacitidine
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 1 people
- Sponsor
- Celgene
Autologous Hematopoietic Stem Cell Transplant
Evaluation of the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.
The goal of this clinical study is to evaluate the safety of cytokine-induced-killer (CIK) cells during early transplant period of autologous hematopoietic stem cell transplant.
- Trial name
- NCT07692607
- Testing
- CIK cells
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- LucasBio
Muscle-Invasive Bladder Carcinoma
Clinical Performance Evaluation of the C2i-Test
The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing…
- Trial name
- NCT05221827
- Testing
- C2i Test
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- C2i Genomics
Colorectal Cancer
EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or…
- Trial name
- CLAUDE (NCT05350501)
- Testing
- EO2040
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Enterome
Participants With Underactive Bladder (UAB)
A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)
The objective of this POC (Phase 2a) study is to evaluate the effect on Bladder Voiding Efficiency (BVE) as well as safety of SFG-02 transdermal formulation in participants with UAB.
- Trial name
- NCT07906106
- Testing
- SFG-02
- Where
- 16 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Juro Sciences Inc.
Acute Myeloid Leukemia (AML)
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR<0.05) AML (FLT3…
- Trial name
- NCT03512197
- Testing
- Midostaurin, Chemotherapy
- Where
- 133 sites in United States, Argentina and 18 more
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Non-Small Cell
Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer.
- Trial name
- LumenDx (NCT06963307)
- Where
- Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Acute Myeloid Leukemia in Remission
Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia
Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and with presence of MRD
- Trial name
- ADVANCE-II (NCT03697707)
- Testing
- DCP-001
- Where
- 10 sites in Finland, Germany and 3 more
- Volunteers
- 20 people
- Sponsor
- Mendus
Breast Cancer
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the…
- Trial name
- NCT01772472
- Testing
- trastuzumab, trastuzumab emtansine
- Where
- 268 sites in United States, Argentina and 26 more
- Volunteers
- 1,486 people
- Sponsor
- Hoffmann-La Roche